AOBO's ZD Pill and CWJ Tablet receive Chinese approval for sales in Hong Kong

NewsGuard 100/100 Score

American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, today announced that the Company's Zhibai Dihuang Pill ("ZD Pill") and Ciwujia Tablet ("CWJ Tablet") have been approved for sale as traditional Chinese medicine ("TCM") in Hong Kong by Chinese Medicine Council of Hong Kong, ("CMCHK").

Guangxi Lingfeng Pharmaceutical, ("GLP"), a wholly owned subsidiary of AOBO, is the manufacturer of ZD Pill, which is formulated entirely with pure natural ingredients and herbs.  The medicine is indicated for the treatment of hot flush, night sweat, dry mouth, sore throat, etc.

Harbin Three Happiness Bioengineering ("3H"), a wholly owned subsidiary of AOBO, is the manufacturer of CWJ Tablet, which is formulated entirely with pure natural ingredients and herbs.  The medicine is indicated for the treatment of fatigue, poor appetite, back pain and knee pain, and insomnia.

Mr. Tony Liu, Chairman and CEO of AOBO, commented, "We are honored to receive the approval for sales of additional two TCMs in Hong Kong.  These newly-approved ZD Pill and CWJ Tablet, together with our LWDH mini Ball approved in March, are among the very few TCM products which are manufactured in mainland China and approved for marketing and sales in Hong Kong."

SOURCE American Oriental Bioengineering, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals nerve changes linked to pain and urinary frequency in recurrent UTI sufferers